Cytokine therapy in eye disease

Archives of Ophthalmology

Volumn 116, Issue 11, 1998, Pages 1514-1516

  Okada, Annabelle A ^a  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; COLONY STIMULATING FACTOR 1; CYTOKINE; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; RECOMBINANT ALPHA INTERFERON; TUMOR NECROSIS FACTOR ALPHA;

AIDS RELATED COMPLEX; BIOTECHNOLOGY; DRUG EFFICACY; EDITORIAL; HUMAN; IMMUNOMODULATION; INFLAMMATORY CELL; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; SUBRETINAL NEOVASCULARIZATION; VITREORETINAL DEGENERATION;

EID: 0031774146     PISSN: 00039950     EISSN: None     Source Type: Journal    
DOI: 10.1001/archopht.116.11.1514     Document Type: Editorial

References (50)

1. Gutterman JU. Cytokine therapeutics: lessons from interferon α. Proc Natl Acad Sci USA. 1994;91:1198-1205.
2. Fung WE. Interferon alpha 2a for treatment of age-related macular degeneration [letter]. Am J Opthalmol. 1991;112:349-350.
3. Brouty-Boye D, Zetter BR. Inhibition of cell motility by interferon. Science. 1980;208:516-518.
4. White CW, Sondheimer HM, Crouch EC, et al. Treatment of pulmonary hemangiomatosis with recombinant interferon alfa-2a. N Engl J Med. 1989;320:1197-1200.
5. Miller JW, Stinson WG, Folkman J. Regression of experimental iris neovascularization with systemic alpha-interferon. Ophthalmology. 1993;100:9-14.
6. Guyer DR, Adamis AP, Gragoudas ES, et al. Systemic antiangiogenic therapy for choroidal neovascularization: what is the role of interferon alfa? Arch Ophthalmol. 1992;110:1383-1384.
7. Gillies MC, Sarks JP, Beaumont PE, et al. Treatment of choroidal neovascularisation in age-related macular degeneration with interferon alfa-2a and alfa-2b. Br J Ophthatmol. 1993;77:759-765.
8. Chan CK, Kempin SJ, Noble SK, Palmer GA. The treatment of choroidal neovascular membranes by alpha interferon: an efficacy and toxicity study. Ophthalmology. 1994;191:289-300.
9. Pharmacological Therapy for Macular Degeneration Study Group. Interferon alfa-2a is ineffective for patients with choroidal neovascularization secondary to age-related macular degeneration: results of a prospective randomized placebo-controlled clinical trial. Arch Ophthalmol. 1997;15:865-872.
10. Kauffmann DJH, van Meurs JC, Mertens DAE, et al. Cytokines in vitreous humor: interleukin-6 is elevated in proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci. 1994;35:900-906.
11. Elner SG, Elner VM, Jaffe GJ, et al. Cytokines in proliferate diabetic retinopathy and proliferative vitreoretinopathy. Curr Eye Res. 1995;14:1045-1053.
12. Elner VM, Scales W, Elner SG, et al. Interleukin-6 (IL-6) gene expression and secretion by cytokine-simulated human retinal pigment epithelial cells. Exp Eye Res. 1992;54:361-368.
13. Elner VM, Strieter RM, Elner SG, et al. Neutrophil chemotactic factor (IL-8) gene expression by cytokine treated retinal pigment epithelial cells. Am J Pathol. 1990;136:745-750.
14. Elner SG, Strieter RM, Elner VM, et al. Monocyte chemotactic protein gene expression by cytokine-treated human retinal pigment epithelial cells. Lab Invest. 1991;64:819-825.
15. Jaffe GJ, Peters WP, Roberts W, et al. Modulation of macrophage colony stimulating factor in cultured human retinal pigment epithelial cells. Exp Eye Res. 1992;54:595-603.
16. de Kozak Y, Hicks D, Chatenoud L, et al. Intraocular TNF in endotoxin- and S-antigen-induced uveitis: in vitro synthesis of TNF by retinal Müller glial and pigment epithelial cells. Reg Immunol. 1994;6:76-80.
17. Geiger K, Howes E, Gallina M, et al. Transgenic mice expressing IFN-γ in the retina develop inflammation of the eye and photoreceptor loss. Invest Ophthalmol Vis Sci. 1994;:35:2667-2681.
18. Okada AA, Sakai J, Usui M, Mizuguchi J. Intraocular cytokine quantification of experimental autoimmune uveoretinitis in rats. Ocular Immunol Inflamm. 1998;6:111-120.
19. Barton K, McLauchlan MT, Clader VL, Lightman S. The kinetics of cytokine mRNA expression in the retina during experimental autoimmune uveoretinitis. Cell Immunol. 1995;164:133-140.
20. Saoudi A, Kuhn J, Huygen K. TH2 activated cells prevent experimental autoimmune uveoretinitis, a TH1-dependent autoimmune disease. Eur J Immunol. 1993;23:3096-3103.
21. Tsambaos D, Eichelberg D, Goos M. Behçet's syndrome: treatment with recombinant leukocyte alpha-interferon. Arch Dermatol Res. 1986;278:335-336.
22. Dündar S, Özcebe OI, Özdemir O. Alpha interferon in the treatment of Behçet's disease. Rev Med Interne. 1993;14:49-50.
23. Azizlerli G, Sarica R, Köse A, et al. Interferon alfa-2a in the treatment of Behçet's disease. Dermatology. 1996;192:239-241.
24. 2b in Behçet's disease. Arth Rheumatism. 1993;36:1025-1026.
25. Feron EJ, Rothova A, van Hagen PM, et al. Inteferon-a2b for refractory ocular Behçet's disease [letter]. Lancet. 1994;343:1428.
26. Kötter I, Eckstein AK, Stübiger N, Zierhut M. Treatment of ocular symptoms of Behçet's disease with interferon a: a pilot study. Br J Ophthalmol. 82:488-494.
27. Okada AA, Keino H, Fukai T, et al. Effect of type I interferon on experimental autoimmune uveoretinitis in rats. Ocular Immunol Inflamm. In press.
28. Ohno S, Kato F, Matsuda H. Detection of gamma interferon in the sera of patients with Behçet's disease. Infect Immunol. 1982;36:202-208.
29. Mustafa MI, Diener P Höjeberg B, et al. T cell immunity and interferon-γ secretion during experimental allergic encephalomyelitis in Lewis rats. J Neuroimmunol. 1991;31:165-177.
30. Noronha A, Toscas A, Jensen MA. Interferon b decreases T cell activation and interferon γ production in multiple sclerosis. J Neuroimmunol. 1993;46:145-154.
31. Rudick RA, Goodkin DE, Jacobs LD, et al. Impact of interferon beta-1a on neurologic disability in relapsing multple sclerosis. Neurology. 1997;49:358-363.
32. Arnason BGW, Dayal A, Qu ZX, et al. Mechanisms of action of interleron-β in multiple sclerosis. Springer Sem Immunopathol. 1996;18:125-148.
33. Beaman MH. Cytokine therapy of infectious diseases. Curr Clin Topics Infect Dis. 1994;14:228-251.
34. Hartshorn K, Vogt M, Chou T, et al. Synergistic inhibition of human immunodeficiency virus in vitro by azidothymidine and recombinant alpha A interferon. Antimicrob Agents Chemother. 1987;31:168-172.
35. Lane HC, Davey V, Kovacs JA, et al. Interferon-alpha in patients with asymptomatic human immunodeficiency virus (HIV) infection: a randomized, placebocontrolled trial. Ann Intern Med. 1990;116:805-811.
36. Fischl MA, Finkelstein DM, He W, et al. A phase II study of recombinant human interferon-alpha 2a and zidovudine in patients with AIDS-related Kaposi's sarcoma. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;11:379-384.
37. Sneller MC. Cytokine therapy of HIV infection. Adv Exp Med Biol. 1996;394:411-419.
38. Jacobsen M, Stanley H, Heard S. Ganciclovir with recombinant metionyl human granulocyte colony-stimulating factor for treatment of cytomegalovirus disease in AIDS patients. AIDS. 1992;6:515-517.
39. Hardy D, Spector S, Polsky B, et al. Combination of ganciclovir and granulocyte-macrophage colony-stimulating factor in the treatment of cytomegalovirus retinitis in AIDS patients. Eur J Clin Microbiol Infect Dis. 1994;13 (suppl 2):S34-40.
40. Conlon KC, Urba WJ, Smith JW, et al. Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy. Cancer. 1990;65:2237-2242.
41. Vial T, Descotes J. Immune-mediated side-effects of cytokines in humans. Toxicology. 1995;105:31-57.
42. Phillips TM. Interferon-a induces renal dysfunction and injury. Curr Opin Nephrol Hypertens. 1996;5:380-383.
43. Guyer DR, Tiedeman J, Yannuzzi LA, et al. Interferon-associated retinopathy. Arch Ophthalmol. 1993;111:350-356.
44. Antonelli G. Development of neutralizing and binding antibodies to interferon (IFN) in patients undergoing IFN therapy. Antiviral Res. 1994;24:235-244.
45. Rollwagen FM, Baqar S. Oral cytokine administration. Immunol Today. 1996;17:548-550.
46. Brod SA, Scott M, Burns DK, Phillips JT. Modification of acute experimental autoimmune encephalomyelitis in the Lewis rat by oral administration of type 1 interferons. J Interferon Cytokine Res. 1995;15:115-122.
47. Oral alpha interferon study starts. AIDS Alert. 1996;11:71.
48. Tartour E, Lee RS, Fridman WH. Anti-cytokines: promising tools for diagnosis and immunotherapy. Biomed Pharmacother. 1994;48:417-424.
49. Dana MR, Yamada J, Streilein JW. Topical interleukin 1 receptor antagonist promotes corneal tranpslantat survival. Transplantation. 1997;63:1501-1507.
50. Tilg H, Mier JW, Vogel W, et al. Induction of circulating IL-1 receptor antagonist by IFN treatment. J Immunol. 150:4687-4692.